{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:46:53Z","timestamp":1791704813861,"version":"4.3.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tranon.2026.103059","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:02:47Z","timestamp":1790589767000},"page":"103059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3582-3824","authenticated-orcid":false,"given":"Qinghua","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.103059_bib0001","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(25)00709-0","article-title":"Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB\u2013IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study","volume":"27","author":"Dummer","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103059_bib0002","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.103059_bib0003","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103059_bib0004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103059_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103059_bib0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB\u2013D melanoma: a phase 1\/2 trial","volume":"31","author":"Dummer","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.103059_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103059_bib0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","article-title":"Slominski AT. How cancer hijacks the body's homeostasis through the neuroendocrine system","volume":"46","author":"Slominski","year":"2023","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.tranon.2026.103059_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102962","article-title":"Adjuvant immunotherapy for melanoma patients: progress and opportunities","volume":"9","author":"Sussman","year":"2024","journal-title":"ESMo Open."},{"issue":"suppl","key":"10.1016\/j.tranon.2026.103059_bib0010","article-title":"INTerpath-001: pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II\u2013IV melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"suppl","key":"10.1016\/j.tranon.2026.103059_bib0011","article-title":"A phase 3 trial comparing fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma","volume":"41","author":"Panella","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:31:52Z","timestamp":1791703912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"alternative-id":["S1936523326003955"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103059","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103059"}}